Skip to main content
. 2019 Apr 24;10:385. doi: 10.3389/fphar.2019.00385

FIGURE 2.

FIGURE 2

Increase in methylation of identified CpGs is cell line-specific. (A) Methylation level of 616 identified probes common in untreated and decitabine-treated (1 μM for 24 h) bladder cancer T24 cell line. An increase in median DNA methylation levels (median Δβ = 0.14) at 616 common CpGs was observed after the drug treatment. (B) Methylation level of 590 identified probes common in mock (DMSO) and decitabine-treated (0.06 μM for 72 h) breast cancer MCF7 cell line. We observed a smaller decrease in methylation level (median Δβ = –0.01, p < 0.005) when the cells were treated with lower dose (0.06 μM) of decitabine in MCF7 cell lines. The statistical significance was assessed using the non-parametric Wilcoxon test. ∗∗∗p < 0.0005.